Related Experiment Video

Updated: Jun 21, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K

Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant

Moritz Kleemiss1, Christa E Müller2, Marion Schneider2

  • 1Department of internal Medicine III, University Hospital Bonn, Bonn, Germany.

Clinical Lung Cancer
|July 10, 2024
PubMed
Abstract

No abstract available in PubMed .

Keywords:
End stage renal disease (ESRD)MET inhibitorMesenchymal-epithelial transition factorPharmacokinetics (PK)Severe renal impairment

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Related Concept Videos